Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial

Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial

Purpose: The phase 3 ATTRACTION-2 study demonstrated that nivolumab monotherapy improved survival compared to placebo in patients with pretreated advanced gastric cancer (AGC). However, the efficacy of nivolumab seems to be limited to a subset of patients. Materials and methods: The predictive value...

Full description

Bibliographic Details
Main Authors: Kang, Y.-K (Author), Kim, D. (Author), Kim, J.H (Author), Lee, S.Y (Author), Ma, J. (Author), Park, Y.S (Author), Ryu, M.-H (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Advanced gastric cancer
B7-H1 Antigen
Biomarkers, Tumor
clinical trial
complication
Epstein Barr virus infection
Epstein-Barr Virus Infections
genetics
human
Humans
metabolism
nivolumab
Nivolumab
pathology
phase 3 clinical trial
Predictive biomarkers
programmed death 1 ligand 1
Stomach Neoplasms
stomach tumor
Survival
tumor marker
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items